drugset / Trial / NCT07267949

Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation

NCT07267949

Phase 2 Recruiting 200 enrolled Acesion Pharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A clinical Randomized Phase 2 Trial of AP31969 versus Placebo for Rhythm Control of Atrial Fibrillation.

Timeline

Start
2025-10-22
Primary completion
2026-11
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AP31969 Unknown 100 mg Oral
Subject AP31969 Unknown 200 mg Oral
Subject AP31969 Unknown 350 mg Oral
Subject AP31969 Unknown 500 mg Oral

Indications